SmartMed Technologies, a provider intelligence in serving the life science, announced that it will invest US$3 million to expand its complex in Seoul.
Online PR News – 13-March-2020 – Yeongdeungpo-gu/SEOUL – SmartMed Technologies expansion will include assessing and optimizing product configurations and adding more industry veterans, market research experts, consultants, and survey statisticians for in-depth quantitative survey research.
SmartMed Technologies’ Chief Medical Officer, Dr. Norman Hammond commented on the expansion saying “Essential research companies foster new discoveries every day. The success of businesses of all sizes is critical to economic vitality, and we at SmartMed Technologies are a leader in this field.”
“Over the next five to 10 years, we see a world where instruments and diagnostics will converge to lead a precision medicine revolution. We are putting a stake at the intersection of science, medicine, and technology to help develop solutions for converging markets that will make a difference in the lives of billions of people for the next century”, added Dr. Norman Hammond, Chief Medical Officer of SmartMed Technologies.
About Us - SmartMed Technologies
SmartMed Technologies is a pioneering SmartMed Technologies medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.
Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.
With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.
With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.